Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/17/2022 | $5.50 | Buy | Canaccord Genuity |
10/18/2021 | $11.00 | Buy | B of A Securities |
10/18/2021 | Buy | BofA Securities | |
10/18/2021 | $13.00 | Outperform | Evercore ISI Group |
10/18/2021 | $11.00 | Outperform | Cowen & Co. |
10/18/2021 | $11.00 | Outperform | RBC Capital |
NEW YORK, Oct. 13, 2023 /PRNewswire/ -- L Catterton and Thorne HealthTech, Inc. ("Thorne") (NASDAQ:THRN) today announced that the tender offer to purchase all of the issued and outstanding shares of Thorne's common stock ("Shares") for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended (such date and time, the "Expiration Time"). Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised L Catterton that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Abcam Plc (NASDAQ:ABCM) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ABCM to Danaher Corporation for $24.00 per share in cash for each share of ABCM common stock owned. If you are an ABCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Thorne HealthTech, Inc. (NASDAQ:THRN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TRHN to L Catter
L Catterton to Commence a Tender Offer for all of Thorne's Outstanding Shares of Common Stock Thorne Stockholders to Receive $10.20 per Share in Cash, Representing a 94% Premium to the Unaffected Price Independent Special Committee and Thorne Board of Directors Unanimously Approve Transaction and Recommend that All Stockholders Tender Their Shares in the Tender Offer NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused inv
15-12G - Thorne Healthtech, Inc. (0001844280) (Filer)
S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)
S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)
Canaccord Genuity initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $5.50
B of A Securities initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $11.00
BofA Securities initiated coverage of Thorne HealthTech with a rating of Buy
NEW YORK, March 13, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ:THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has appointed Saloni Varma as Chief Financial Officer (CFO). As CFO, Varma will lead all aspects of the company's Accounting and Finance functions including budgeting planning and analysis, accounting, SEC reporting, tax, treasury, and investor relations. Varma brings more than 20 years of experience across a range of consumer goods companies, mos
SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)
SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)
SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)
4 - Thorne Healthtech, Inc. (0001844280) (Issuer)
4 - Thorne Healthtech, Inc. (0001844280) (Issuer)
4 - Thorne Healthtech, Inc. (0001844280) (Issuer)
Record Net Sales With Growth of 33.1%; Raises Full-Year Guidance Midpoints for Net Sales and Gross Margin NEW YORK, Aug. 8, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter Highlights: Net sales grew 33.1% year-over-year to $72.7 million, with direct-to-consumer ("DTC") sales growth of 39.3%Gross profit grew 35.7% year-over-year to $40.6 million; gross profit as a % of net sales increased year-over-year to 55.9%.Net incom
Company Withdraws Participation in the Canaccord Genuity 43rd Annual Growth Conference on Aug. 10 NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its second quarter 2023 financial results after market close on Tuesday, Aug. 8, 2023. The company will host a conference call to discuss its results on Tuesday, Aug. 8, 2023, at 5:00 p.m. (U.S. Eastern Time). A live webcast and replay of the call will be available on the investors section of the
Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK, May 11, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Highlights: Net sales grew 20.7% year-over-year to $65.2 million, with direct-to-consumer ("DTC") sales growth of 41.0%Gross profit grew 16.3% year-over-year to $34.3 million; gross p